GLP-1

GLP-1 receptor agonists and noncardiometabolic outcomes - EurekAlert!

As demand for GLP-1 pills and shots surges, healthy habits are still key

GLP-1 microdosers are chasing longevity

Beyond weight loss—how the GLP-1 story is evolving

Wegovy may have highest eye stroke and sight loss risk of semaglutide GLP-1 agonists— Odds of ischaemic optic neuropathy(caused by inadequate/interrupted blood flow to the optic nerve, resulting in sudden vision loss in one or both eyes) nearly 5 times higher than among users of Ozempic

Holding vs continuing GLP-1/GIP agonists before upper endoscopy - EurekAlert!

What happens when patients stop taking GLP-1 drugs? New Cleveland Clinic study reveals real world insights - EurekAlert!

Wegovy may have highest ‘eye stroke’ and sight loss risk of semaglutide GLP-1 agonists - EurekAlert!

Digital microsteps as scalable adjuncts for adults using GLP-1 receptor agonists - EurekAlert!

How do GLP-1 agonists affect gene expression? - EurekAlert!

Novel plant-based approach to a better, cheaper GLP-1 delivery system - EurekAlert!

GLP-1 diabetes drugs linked to reduced risk of addiction and substance-related death - EurekAlert!

GLP-1 diabetes medications lower risk of all kinds of substance use disorders, study finds

GLP-1 drugs linked to lower addiction rates in large study of veterans

GLP-1 drugs like Ozempic could cut risk of major heart complications after heart attack, study finds - EurekAlert!

GLP-1 weight-loss drugs comparably effective for patients across age, race, and starting weight - EurekAlert!

Heterogeneity of treatment effects of GLP-1 RAs for weight loss in adults - EurekAlert!

GLP-1 drugs associated with reduced need for emergency care for migraine - EurekAlert!

Understanding GLP-1 signaling: A path to better therapies - EurekAlert!

The Lancet: New weight loss pill leads to greater blood sugar control and weight loss for people with diabetes than current oral GLP-1, phase 3 trial finds - EurekAlert!